Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Center of Clinical Laboratory, Hangzhou Ninth People's Hospital, Hangzhou, China.
BMC Cancer. 2022 Mar 12;22(1):264. doi: 10.1186/s12885-022-09322-9.
With the improved knowledge of disease biology and the introduction of immune checkpoints, there has been significant progress in treating renal cell carcinoma (RCC) patients. Individual treatment will differ according to risk stratification. As the clinical course varies in RCC, it has developed different predictive models for assessing patient's individual risk. However, among other prognostic scores, no transparent preference model was given. MicroRNA as a putative marker shown to have prognostic relevance in RCC, molecular analysis may provide an innovative benefit in the prophetic prediction and individual risk assessment. Therefore, this study aimed to establish a prognostic-related microRNA risk score model of RCC and further explore the relationship between the model and the immune microenvironment, immune infiltration, and immune checkpoints. This practical model has the potential to guide individualized surveillance protocols, patient counseling, and individualized treatment decision for RCC patients and facilitate to find more immunotherapy targets.
Downloaded data of RCC from the TCGA database for difference analysis and divided it into a training set and validation set. Then the prognostic genes were screened out by Cox and Lasso regression analysis. Multivariate Cox regression analysis was used to establish a predictive model that divided patients into high-risk and low-risk groups. The ENCORI online website and the results of the RCC difference analysis were used to search for hub genes of miRNA. Estimate package and TIMER database were used to evaluate the relationship between risk score and tumor immune microenvironment (TME) and immune infiltration. Based on Kaplan-Meier survival analysis, search for immune checkpoints related to the prognosis of RCC.
There were nine miRNAs in the established model, with a concordance index of 0.702 and an area under the ROC curve of 0.701. Nine miRNAs were strongly correlated with the prognosis (P < 0.01), and those with high expression levels had a poor prognosis. We found a common target gene PDGFRA of hsa-miR-6718, hsa-miR-1269b and hsa-miR-374c, and five genes related to ICGs (KIR2DL3, TNFRSF4, LAG3, CD70 and TNFRSF9). The immune/stromal score, immune infiltration, and immune checkpoint genes of RCC were closely related to its prognosis and were positively associated with a risk score.
The established nine-miRNAs prognostic model has the potential to facilitate prognostic prediction. Moreover, this model was closely related to the immune microenvironment, immune infiltration, and immune checkpoint genes of RCC.
随着对疾病生物学的深入了解和免疫检查点的引入,肾细胞癌 (RCC) 患者的治疗取得了重大进展。根据风险分层,个体治疗会有所不同。由于 RCC 的临床病程不同,因此已经开发出不同的预测模型来评估患者的个体风险。然而,在其他预后评分中,没有给出透明的偏好模型。miRNA 作为一种具有 RCC 预后相关性的假定标志物,分子分析可能为预测和个体风险评估提供创新性益处。因此,本研究旨在建立 RCC 的预后相关 miRNA 风险评分模型,并进一步探讨该模型与免疫微环境、免疫浸润和免疫检查点之间的关系。这种实用的模型有可能指导 RCC 患者的个体化监测方案、患者咨询和个体化治疗决策,并有助于发现更多的免疫治疗靶点。
从 TCGA 数据库中下载 RCC 数据进行差异分析,并将其分为训练集和验证集。然后通过 Cox 和 Lasso 回归分析筛选出预后基因。多变量 Cox 回归分析用于建立将患者分为高风险和低风险组的预测模型。使用 ENCORI 在线网站和 RCC 差异分析结果搜索 miRNA 的枢纽基因。使用 Estimate 包和 TIMER 数据库评估风险评分与肿瘤免疫微环境 (TME) 和免疫浸润之间的关系。基于 Kaplan-Meier 生存分析,搜索与 RCC 预后相关的免疫检查点。
建立的模型中有 9 个 miRNA,一致性指数为 0.702,ROC 曲线下面积为 0.701。这 9 个 miRNA 与预后强烈相关 (P<0.01),且高表达者预后较差。我们发现 hsa-miR-6718、hsa-miR-1269b 和 hsa-miR-374c 与 PDGFRA 有共同的靶基因,以及与 ICGs 相关的五个基因 (KIR2DL3、TNFRSF4、LAG3、CD70 和 TNFRSF9)。RCC 的免疫/基质评分、免疫浸润和免疫检查点基因与预后密切相关,并与风险评分呈正相关。
建立的九个 miRNA 预后模型有可能促进预后预测。此外,该模型与 RCC 的免疫微环境、免疫浸润和免疫检查点基因密切相关。